817 related articles for article (PubMed ID: 29976060)
1. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
2. Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide.
Pauletti GM; Gangwar S; Okumu FW; Siahaan TJ; Stella VJ; Borchardt RT
Pharm Res; 1996 Nov; 13(11):1615-23. PubMed ID: 8956324
[TBL] [Abstract][Full Text] [Related]
3. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
5. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide.
Pauletti GM; Gangwar S; Wang B; Borchardt RT
Pharm Res; 1997 Jan; 14(1):11-7. PubMed ID: 9034215
[TBL] [Abstract][Full Text] [Related]
6. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.
Gupta SV; Gupta D; Sun J; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2011 Dec; 8(6):2358-67. PubMed ID: 21905667
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds.
Chan OH; Schmid HL; Stilgenbauer LA; Howson W; Horwell DC; Stewart BH
Pharm Res; 1998 Jul; 15(7):1012-8. PubMed ID: 9688053
[TBL] [Abstract][Full Text] [Related]
9. Optimizing oral absorption of peptides using prodrug strategies.
Borchardt RT
J Control Release; 1999 Nov; 62(1-2):231-8. PubMed ID: 10518655
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
11. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides.
Ovadia O; Greenberg S; Chatterjee J; Laufer B; Opperer F; Kessler H; Gilon C; Hoffman A
Mol Pharm; 2011 Apr; 8(2):479-87. PubMed ID: 21375270
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
13. Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Ohura K; Soejima T; Nogata R; Adachi Y; Ninomiya S; Imai T
J Pharm Sci; 2012 Sep; 101(9):3264-74. PubMed ID: 22628163
[TBL] [Abstract][Full Text] [Related]
14. Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.
Hess S; Ovadia O; Shalev DE; Senderovich H; Qadri B; Yehezkel T; Salitra Y; Sheynis T; Jelinek R; Gilon C; Hoffman A
J Med Chem; 2007 Nov; 50(24):6201-11. PubMed ID: 17983214
[TBL] [Abstract][Full Text] [Related]
15. Transport of levovirin prodrugs in the human intestinal Caco-2 cell line.
Li F; Hong L; Mau CI; Chan R; Hendricks T; Dvorak C; Yee C; Harris J; Alfredson T
J Pharm Sci; 2006 Jun; 95(6):1318-25. PubMed ID: 16634069
[TBL] [Abstract][Full Text] [Related]
16. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug.
Okudaira N; Tatebayashi T; Speirs GC; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Aug; 294(2):580-7. PubMed ID: 10900235
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability.
Wang B; Wang W; Camenisch GP; Elmo J; Zhang H; Borchardt RT
Chem Pharm Bull (Tokyo); 1999 Jan; 47(1):90-5. PubMed ID: 9987829
[TBL] [Abstract][Full Text] [Related]
18. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.
Yoshigae Y; Imai T; Aso T; Otagiri M
Life Sci; 1998; 62(14):1231-41. PubMed ID: 9570338
[TBL] [Abstract][Full Text] [Related]
19. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
Ouyang H; Tang F; Siahaan TJ; Borchardt RT
Pharm Res; 2002 Jun; 19(6):794-801. PubMed ID: 12134949
[TBL] [Abstract][Full Text] [Related]
20. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs.
Föger F; Kopf A; Loretz B; Albrecht K; Bernkop-Schnürch A
Amino Acids; 2008 Jun; 35(1):233-41. PubMed ID: 17726639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
